

Gerrit Jan Wolbink

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8102588/gerrit-jan-wolbink-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

11,504
citations

57
h-index

106
g-index

140
ext. papers

13,062
ext. citations

5.5
avg, IF

5.87
L-index

#	Paper	IF	Citations
137	Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-8	1.9	2
136	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2022 , 8, e002216	5.9	1
135	Elevated Fab glycosylation of anti-hinge antibodies. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-8	1.9	1
134	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	54
133	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. <i>Trials</i> , 2021 , 22, 406	2.8	
132	Comment on Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialSby Tanaka. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e172	2.4	3
131	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. <i>Science</i> , 2021 , 371,	33.3	98
130	Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3162-3176	3.8	1
129	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology, The</i> , 2021 , 3, e778-e788	14.2	40
128	Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e542-e545	14.2	20
127	Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
126	Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1417-1425	2.8	3
125	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020 , 11, 312	8.4	39
124	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2129-2137	4.3	4
123	The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2020 , 59, 1703-1708	3.9	3
122	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology, The</i> , 2020 , 2, e583-e585	14.2	23
121	Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2005-2016	9.5	2

120	Response to: Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study by Marotte. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e82	2.4	
119	Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses. <i>European Journal of Immunology</i> , 2020 , 50, 1113-1125	6.1	7
118	The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 306-313	2.2	9
117	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	22
116	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 837-848	5.1	30
115	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 266-270	1.9	7
114	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1055-1061	2.4	12
113	Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 66	5.7	7
112	Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 869-873	2.3	5
111	Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. <i>Journal of Rheumatology</i> , 2019 , 46, 117-118	4.1	0
110	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 484-487	2.4	44
109	Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra micro sampler vs dried blood spot. <i>Bioanalysis</i> , 2018 , 10, 815-823	2.1	30
108	Response to: Comment on LSAmi titled Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial by den Broeder. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e68	2.4	
107	Restricted immune activation and internalisation of anti-idiotypic complexes between drug and antidrug antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1471-1479	2.4	13
106	Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1285-1288	2.4	13
105	Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2474-2484	3.8	22
104	Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes. <i>Journal of Immunology</i> , 2017 , 198, 82-93	5.3	16
103	Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1035-1037.e6	11.5	16

102	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1170-6	2.4	54
101	Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. <i>Arthritis Research and Therapy</i> , 2016 , 18, 290	5.7	15
100	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 578-85	2.4	119
99	Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 120, 198-201	3.5	15
98	Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e24	2.4	9
97	Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. <i>Scientific Reports</i> , 2016 , 6, 32747	4.9	28
96	Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. <i>Oncologist</i> , 2016 , 21, 1260-1268	5.2	52
95	Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 655-62	2.2	4
94	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e15	2.4	49
93	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. <i>British Journal of Dermatology</i> , 2015 , 173, 855-7	4	27
92	Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. <i>Arthritis Research and Therapy</i> , 2015 , 17, 78	5.7	28
91	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1825-9	2.4	41
90	Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. <i>Journal of Rheumatology</i> , 2015 , 42, 1638-46	4.1	23
89	Key findings towards optimising adalimumab treatment: the concentration-effect curve. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 513-8	2.4	122
88	The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 311-4	2.4	82
87	Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1915-23	2.4	45
86	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 361-8	2.4	61
85	IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3124-34	9.5	22

84	Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2015 , 418, 29-38	2.5	57
83	Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 396-401	2.4	55
82	Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2217-9	2.4	30
81	Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1133-40	9.5	30
80	The minipig as an alternative non-rodent model for immunogenicity testing using the TNF α blockers adalimumab and infliximab. <i>Journal of Immunotoxicology</i> , 2014 , 11, 62-71	3.1	17
79	Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2178-82	2.4	55
78	Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. <i>Journal of Biological Chemistry</i> , 2014 , 289, 34482-8	5.4	44
77	Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2791-802		32
76	Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF α biologics in rheumatic diseases. <i>Clinical Rheumatology</i> , 2013 , 32, 1429-35	3.9	70
75	Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. <i>Rheumatology</i> , 2013 , 52, 547-53	3.9	52
74	Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 164-72	8.1	292
73	Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 2013 , 437, 118-22	3.1	10
72	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , 2013 , 9, e1003394	6	127
71	Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. <i>Rheumatology</i> , 2013 , 52, 1462-6	3.9	3
70	Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. <i>Rheumatology</i> , 2013 , 52, 631-5	3.9	36
69	Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 104-9	2.4	205
68	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 593-600	5	84
67	Long-term measurement of anti-adalimumab using pH-shift-anti-idiotypic antigen binding test shows predictive value and transient antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1680-6	2.4	72

66	Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. <i>Journal of Immunological Methods</i> , 2012 , 375, 93-9	2.5	63
65	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3850-5		61
64	Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1914-5	2.4	161
63	The acute-phase response is not predictive for the development of arthritis in seropositive arthralgia - a prospective cohort study. <i>Journal of Rheumatology</i> , 2012 , 39, 1914-7	4.1	12
62	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012 , 13, 184	2.8	23
61	IgG4 production against adalimumab during long term treatment of RA patients. <i>Journal of Clinical Immunology</i> , 2012 , 32, 1000-6	5.7	51
60	Immunogenicity of biological therapeutics: from assay to patient. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 306-11	5.3	56
59	Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 88-91	2.4	106
58	Differential effect of drug interference in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2011 , 372, 196-203	2.5	132
57	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011 , 12, 12	2.8	27
56	Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 877-83		83
55	Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3226-33		158
54	The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 284-8	2.4	131
53	Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. <i>Analytical Biochemistry</i> , 2011 , 411, 271-6	3.1	48
52	The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 128-33 ^{2.4}		131
51	Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1460-8	27.4	538
50	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010 , 42, 508-14	36.3	969
49	Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 817-21	2.4	155

48	Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 624-5	2.4	70
47	Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1281-5	2.4	42
46	Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. <i>Archives of Dermatology</i> , 2010 , 146, 127-32		113
45	Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 409-12	2.4	65
44	Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 490-4	2.4	189
43	Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R221	5.7	52
42	The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. <i>Arthritis Research and Therapy</i> , 2010 , 12, 217	5.7	76
41	A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2010 , 362, 82-8	2.5	135
40	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61		74
39	A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1303-9	2.4	68
38	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1787-8	2.4	67
37	Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 531-5	2.4	105
36	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. <i>Human Mutation</i> , 2009 , 30, E640-50	4.7	119
35	Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1324-30		84
34	Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1484-90		78
33	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009 , 41, 1313-8	36.3	272
32	Dealing with immunogenicity of biologicals: assessment and clinical relevance. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 211-5	5.3	138
31	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. <i>Nature Genetics</i> , 2008 , 40, 1216-23	36.3	416

30	Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1122-6	6.1	169
29	The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1139-44	2.4	100
28	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1697-701	2.4	35
27	Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. <i>Current Opinion in Immunology</i> , 2008 , 20, 431-5	7.8	151
26	IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 425-8	4.1	16
25	Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1972-7	4.1	43
24	Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 958-61	2.4	73
23	Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 133-4	2.4	42
22	Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 253-6	2.4	132
21	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 921-6	2.4	396
20	Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1252-4	2.4	98
19	Do C-reactive protein levels help predict onset of rheumatoid arthritis in women?. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 318-9		
18	Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 711-5		384
17	High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1249-50	2.4	25
16	The effects of continuous venovenous hemofiltration on coagulation activation. <i>Critical Care</i> , 2006 , 10, R150	10.8	21
15	Detection of soluble human granzyme K in vitro and in vivo. <i>European Journal of Immunology</i> , 2005 , 35, 2940-8	6.1	43
14	Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2740-50		399
13	Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 704-7	2.4	165

12	Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 252-5	4.1	73
11	Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2996-7		37
10	Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. <i>Journal of Hepatology</i> , 2000 , 32, 783-91	13.4	41
9	C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. <i>Circulation</i> , 1999 , 100, 96-102	16.7	665
8	Complement activation in patients with sepsis is in part mediated by C-reactive protein. <i>Journal of Infectious Diseases</i> , 1998 , 177, 81-7	7	69
7	Inhibition of human complement by beta-glycyrrhetic acid. <i>Immunology</i> , 1997 , 90, 115-20	7.8	86
6	C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. <i>Circulation</i> , 1997 , 95, 97-103	16.7	250
5	Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. <i>Journal of Immunological Methods</i> , 1993 , 163, 67-76	2.5	101
4	The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. <i>British Journal of Cancer</i> , 1992 , 65, 96-101	8.7	42
3	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992 , 79, 693-698		114
2	Interplay of complement and cytokines in the pathogenesis of septic shock. <i>Immunopharmacology</i> , 1992 , 24, 135-48		43
1	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992 , 79, 693-698		1